SequelSEC

MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI

Pharmaceutical Preparations · CIK 0001823239 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$208.78M
Fiscal year ended 2026-06-30
Operating income
-$117.07M
Fiscal year ended 2026-06-30
Free cash flow
-$35.84M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$300.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue1.6×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin18.3%9th
R&D / revenue9.4%14th
CapEx / revenue7.1%71th
Revenue YoY growth-28.3%30th
Current ratio6.60x67th
Long-term debt / equity0.77x65th
Net margin-70.4%58th
FCF margin-38.1%57th
Operating margin-115.9%57th
SBC / revenue16.2%43th

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $208.78M and net income of -$77.39M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from MARAVAI LIFESCIENCES HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MARAVAI LIFESCIENCES HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$208.78M
Cost of revenue$135.93M
Gross profit$72.85M
Operating income-$117.07M
Net income-$77.39M
Research & development$15.22M
Weighted-average diluted sharesUnavailable
Pretax income-$136.49M
Income tax expense-$408.00K
Diluted EPSUnavailable
Selling, general & administrative$128.14M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

MARAVAI LIFESCIENCES HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$70.09M
Total assets$603.75M
Current assets$155.66M
Total liabilities$248.16M
Current liabilities$38.42M
Total equity incl. NCI$355.59M
Temporary (mezzanine) equityUnavailable
Inventory$41.23M
Accounts receivable$31.14M
Goodwill$129.43M
Long-term debt$145.98M
Accounts payable$7.12M

Cash flow

MARAVAI LIFESCIENCES HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$25.26M
Capital expenditures$10.58M
Investing cash flow-$9.85M
Financing cash flow-$164.27M
Net change in cash-$199.33M
Stock-based compensation$29.93M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

MARAVAI LIFESCIENCES HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$35.84M
Gross margin34.9%
Operating margin-56.1%
FCF margin-17.2%
SBC / revenue14.3%
Current ratio4.05x
Revenue YoY growth-5.0%
Net margin-37.1%
R&D / revenue7.3%
CapEx / revenue5.1%
Long-term debt / equity0.41x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MRVI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.